Maple Securities USA’s Alexion Pharmaceuticals ALXN Stock Holding History

Maple Securities USA’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,943	Closed	-$351K	–	203
2015 Q2	$351K	Sell	1,943 -1,099	-36%	-$190K	0.03%	173
2015 Q1	$527K	Buy	+3,042	New	+$551K	0.04%	108
2014 Q4	–	Sell	-5,250	Closed	-$871K	–	280
2014 Q3	$871K	Buy	+5,250	New	+$862K	0.1%	54
2013 Q3	–	Sell	-10,238	Closed	-$944K	–	536
2013 Q2	$944K	Buy	+10,238	New	+$987K	0.09%	191

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Maple Securities USA's ALXN Position: Q3 2015 in Review

Maple Securities USA sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 1,943 shares — an estimated $351K sold.

Maple Securities USA first reported a position in ALXN in Q2 2013 and held it in 4 quarters. The position peaked at $944K in Q2 2013. 513 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

Maple Securities USA reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Maple Securities USA sold 1,943 Alexion Pharmaceuticals shares in Q3 2015, an estimated $351K.
Maple Securities USA first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Maple Securities USA's Alexion Pharmaceuticals position peaked at $944K in Q2 2013.
513 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Maple Securities USA's 13F filing for Q3 2015, filed 3 Nov 2015.